$13.05
arrow_drop_up4.23%Key Stats | |
---|---|
Open | $12.72 |
Prev. Close | $12.52 |
EPS | -1.50 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 12.55 | 13.14 |
52 Week Range | 6.01 | 13.14 |
Ratios | |
---|---|
EPS | -1.50 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024 - GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
Navigating 6 Analyst Ratings For Zymeworks